key: cord-0712153-jkpfwolw
authors: van Ommen, C. Heleen; Albisetti, Manuela; Bhatt, Mohir; Bonduel, Marianne; Branchford, Brian; Chalmers, Elizabeth; Chan, Anthony; Goldenberg, Neil A.; Holzhauer, Susanne; Monagle, Paul; Nowak‐Göttl, Ulrike; Revel‐Vilk, Shoshana; Sciuccatie, Gabriela; Sirachainan, Nongnuch; Male, Christoph
title: International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis
date: 2021-03-31
journal: J Thromb Haemost
DOI: 10.1111/jth.15260
sha: 294756556ea3eedb91393c491c4348ac4894af3a
doc_id: 712153
cord_uid: jkpfwolw

Pediatric thromboembolism is a rare and heterogenous disease. As a result, there is a paucity of knowledge with regard to natural history, management, and outcomes of most types of pediatric venous and arterial thromboembolism. International research collaboration is needed to fill these knowledge gaps. Not only randomized controlled trials, but also representative observational studies are required to answer all research questions. Therefore, the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis initiated the International Pediatric Thrombosis Network (IPTN). The aims of the IPTN include (1) development of the Throm‐PED registry to facilitate international prospective observational studies, and (2) establishment of a network of pediatric thrombosis centers experienced in effectively conducting clinical trials and observational studies. The IPTN needs dedicated clinicians all over the world and several funding sources to obtain high‐quality research data to reach its ultimate goal of improving care in children with thrombosis. The aim of this communication is to call for active participation in the IPTN to all physicians taking care of children with thrombosis worldwide.

The overall incidence of thrombosis in children is very low. In adults, the overall incidence in the general population is 1 to 2 per 1000 person-years. 1 In children, a recent Danish nationwide pediatric population study reported incidences of 2.1 and 0.3 per 100,000 person years for venous and noncerebral arterial thrombosis, respectively. 2 However, thromboembolism (TE) is increasingly diagnosed in hospitalized children, as result of the increased number of children with underlying medical conditions and hypercoagulability, medical and technologic developments, and heightened awareness.

The frequency of hospital-acquired pediatric venous TE increased from 5.3 events per 10,000 pediatric hospital admissions in the 1990s to approximately 58 events in the early 2000s. 3, 4 Morbidity of venous or arterial TE in children can be substantial. The recurrence rate following a venous TE is reported to be between 2% and 21%, depending on the study type and population studied; and post-thrombotic syndrome develops in approximately 30% of the patients. [5] [6] [7] Hospital-acquired venous TE in children is associated with an increased length of stay and costs. 8 Morbidity after arterial TE is less studied, but consists of limb or organ necrosis, reperfusion injury, hypertension, and leg growth retardation. 9 Mortality due to venous TE varies between 0 and 2.2%. 10 Optimal management and prevention strategies are crucial to decrease the occurrence of these potentially life-threatening complications in children. Unfortunately, in the last decades little progress has been made in generating evidence to substantiate these strategies. Due to the rarity and heterogeneity of pediatric TEs, international research collaboration is indispensable to take a step forward in creating evidence-based management and prevention guidelines. Therefore, the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis has initiated the International Pediatric Thrombosis Network (IPTN). The IPTN aims (1) to enable large, prospective international observational studies using the Throm-PED registry, a prospective international disease-based registry, and (2) to provide a framework for a network of pediatric thrombosis centers with clinical trial experience and infrastructure to efficiently conduct large trials. The goal of this SSC communication is a call for dedicated participation in the IPTN to all physicians taking care of children with thrombosis worldwide. The successful outcome of the IPTN, and as a consequence of international research collaboration in the field of pediatric thrombosis, depends on active collaboration of many centers from all continents.

Pediatric thrombosis is not only a rare, but also a heterogeneous disease. The incidence of venous TE peaks in early infancy and adolescence with about 20% and 50% of venous thromboembolism (VTE) events occurring in children 0 to 1 and 11 to 18 years of age, respectively. 3, 11 More than 90% of neonatal thrombi are catheterrelated, whereas in adolescence 50% of thrombi are associated with indwelling catheters. Incidences and types of thrombotic risk factors in adolescents differ widely depending on the study design and studied patient population, but include surgery, immobility, cardiac disease, thrombophilia, sepsis, malignancy, surgery, and combined oral contraceptive pills. [11] [12] [13] Thrombosis locations vary accordingly: most neonatal thrombi are located in the portal venous hepatic system, right atrium, and renal or caval vein, while the majority of the adolescent thrombi are located in the lower and upper extremities.

In children between 2 and 12 years of age, almost 50% of venous TE are located in the cerebral sinus, as a complication of mastoiditis, asparaginase therapy for treatment of acute lymphoblastic leukemia, or trauma. 6, 14 While arterial thrombosis in adults usually results from atherosclerotic disease, pediatric non-cerebral arterial thrombosis mainly collaboration is needed to fill these knowledge gaps. Not only randomized controlled trials, but also representative observational studies are required to answer all research questions. Therefore, the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis initiated the International Pediatric Thrombosis Network (IPTN). The aims of the IPTN include (1) development of the Throm-PED registry to facilitate international prospective observational studies, and (2) establishment of a network of pediatric thrombosis centers experienced in effectively conducting clinical trials and observational studies. The IPTN needs dedicated clinicians all over the world and several funding sources to obtain high-quality research data to reach its ultimate goal of improving care in children with thrombosis. The aim of this communication is to call for active participation in the IPTN to all physicians taking care of children with thrombosis worldwide.

network, observational, pediatric, registry, thromboembolism develops as result of indwelling catheters or cardiac catheterization in neonates and young infants. 15 Arterial ischemic stroke (AIS) occurs in both neonates and children with an estimated incidence between 1 per 1600 to 5000 live births, and about 1.2 to 7.9 per 100,000 children per year, respectively. 16 Risk factors for neonatal AIS include maternal, antenatal, intrapartum, and postnatal factors, such as maternal smoking, male sex, low Apgar scores, and sepsis.

Pediatric AIS has a heterogeneous etiology as well, including arteriopathy, sickle cell disease, congenital heart disease, coagulopathy, and metabolic disorders. 17 Each type of pediatric venous or arterial TE, such as neonatal renal vein thrombosis, catheter-related arterial thrombosis, or estrogen-associated pulmonary embolism (PE), has its own acute and long-term complications. Thus, studies of renal vein thrombosis should include renal function and hypertension, and studies of arterial thrombosis should include systemic blood pressure, limb or organ necrosis, and extremity length and circumference. 15, 18 In addition, the risk-benefit ratio of anticoagulant treatment varies according to thrombosis location and patient age. For example, due to increased risk of intraventricular hemorrhage the bleeding risk of anticoagulation in preterm neonates with sinovenous thrombosis is probably higher than that in adolescents with estrogen-associated deep vein thrombosis.

Hence, compared to adults, pediatric thromboembolic events are rare and differ significantly in epidemiology. They are heterogeneous with regard to patient age, comorbidity, risk factors, and anatomical location and have their unique pathophysiology, and short-and long-term consequences. 19 One could consider each type of pediatric thromboembolic event an individual rare disease. 19 

As result of the rarity and heterogeneity of pediatric TE, high-quality evidence for the management of most types of pediatric TE is not available, as reflected in the recent American Society of Hematology Most of the hitherto key anticoagulants, including unfractionated heparin, low molecular weight heparin (LMWH), and vitamin K antagonists, are not approved by regulatory agencies for use in children due to lack of randomized clinical trials (RCTs). The only US Food and Drug Administration (FDA)-approved anticoagulant for use in children >1 month of age is the LMWH dalteparin. FDA approval was based on evidence from two single-arm multi-center clinical trials conducted in a total of 52 pediatric patients-including one industrysponsored registrational trial and one investigator-initiated trial. 21, 22 Performing RCTs on anticoagulants in children has proven to be very challenging. The low incidence of pediatric TE has been an important hurdle. Furthermore, in contrast to adults, TE predominantly occurs in sick children, and consequently, many affected patients are excluded from studies. Moreover, parents are reluctant to give consent, particularly when their children are young and very sick. Thus, pediatric anticoagulation RCTs require multiple centers around the world to include sufficient numbers of children. This is reflected in the industry-sponsored pivotal trials on direct oral anticoagulants (DOAC), which are currently ongoing or have just been completed. 6, [23] [24] [25] [26] [27] For example, the rivaroxaban phase 3 study required 107 pediatric hospitals in 28 countries to recruit 500 patients. 6 (Table 1) . Unfortunately, due to the rarity of all those specific types of pediatric TE, RCTs will not be able to answer most of these identified research questions.

It will be important to take other approaches to generate pediatric evidence, for example by representative multicenter longitudinal observational studies. As the number of patients per center is limited, international collaboration is essential to enable high-quality research to improve the evidence on the natural history and the appropriate management of all types of pediatric thrombosis.

To empower international research collaboration in pediatric thrombosis, the IPTN was initiated at the ISTH SSC Subcommittee on Even regulatory authorities such as the US FDA and the European Medicines Agency are increasingly using registries for medication regulation. 33, 34 To further stimulate international research collaboration in pediatric thrombosis, the IPTN will serve as a platform for the Throm-PED Clinical Trial Network, a network of pediatric thrombosis centers with clinical trial experience and infrastructure to effectively conduct both investigator-initiated academic trials and industrysponsored regulatory trials in pediatric thrombosis. Pediatric experts of this network will contribute to the design of the trials by developing clinically relevant and feasible study protocols, assess the feasibility of running these trials among centers of the network, act as contact for industry to roll out these trials in the network, and collaborate with patient representatives to address patient needs.

The current structure of the IPTN is shown in Figure 1 . The executive committee of the IPTN consists of pediatric thrombosis experts from various continents. 28 Each member of the IPTN collects data for the general Throm-PED registry and can propose substudies using the Throm-PED registry. These proposals are discussed in the general assembly meeting, which takes place at least once a year during the ISTH congress. Each approved substudy has its own scientific board, which is responsible for the design and execution of the substudy. At present, the IPTN data management team

Natural history • What is the natural history of (a)symptomatic catheter-related VTE, renal VTE, and (a)symptomatic SVT in neonates? • What is the natural history of asymptomatic VTE, (catheter-related) superficial VTE, large DVT and submassive and massive PE, (a) symptomatic SVT, and right atrial thrombosis in children? • What is the natural history of catheter-related ATE in infants and young children?

• What is the role of radiological screening for asymptomatic catheterrelated VTE and ATE?

• What are the benefits of anticoagulation versus no anticoagulation in neonates and children with asymptomatic VTE, portal vein thrombosis, and SVT; in neonates with renal VTE; and in children with (catheterrelated) superficial VTE? • When is thrombolysis or thrombectomy indicated in neonates and children with right atrial thrombosis and SVT; and in children with large DVT, submassive and massive PE? • What is the risk/benefit of catheter-directed thrombolysis and the minimal infrastructure, experience, and annual case load needed compared to systemic thrombolysis in treatment of VTE? • What is the optimal timing of catheter removal in children with catheterrelated VTE? • When and in which subgroups of patients is antithrombin replacement therapy appropriate in addition to heparin in the treatment of thrombosis? • What is the optimal duration of anticoagulation in (catheter-related) superficial VTE, if needed, in SVT, and in unprovoked VTE in children? • What is the impact of various risk factors to the optimal duration of anticoagulation in VTE? • What is the mortality, recurrence risk, major bleeding risk, and quality of life outcomes for various treatment duration in children with unprovoked VTE? • Which biomarkers or other factors can be used to predict recurrence in children with unprovoked VTE? • What is the optimal intensity, duration, and modality of antithrombotic treatment for pediatric patients with catheter-related ATE?

• What are the risk factors for poor acute and long-term outcome of catheter-related ATE? • What is the impact of vitamin K antagonists versus low-molecular weight heparin on bone density for long-term treatment? • What is the effect of direct oral anticoagulants on menstrual bleeding in teenagers?

Abbreviations: ATE, arterial thromboembolic event; DVT, deep vein thrombosis; PE, pulmonary embolism; SVT, sinovenous thrombosis; VTE, venous thromboembolic event TA B L E 1 Some knowledge gaps in pediatric thrombosis 20, 38, 39 consists of data managers and controllers from the Erasmus Medical Center in Rotterdam, Royal Children's Hospital in Melbourne, and ISTH. With funding, the IPTN will be able to make use of a Data

Coordinating Center that will help with study and database design, development of statistical analysis plans, data management including monitoring and quality checks, and all data analyses.

The multinational Throm-PED registry will offer unique research opportunities. By systemically and prospectively collecting patient 

Overall, the success of disease registries is dependent on three quality criteria: quality of structure, quality of process, and quality of data. 36 The quality of structure needs to be guaranteed by a To increase the quality of data collection standardization is essential, which requires defined research protocols. A monitoring plan and regular audits are needed; not only to address deficiencies in standardization, but also to increase the quality of data by identifying outlying data and following-up on missing data. Abovementioned conditions for a successful disease registry require sufficient resources and funding to ensure long-term sustainability. In addition, development and operation of the Throm-PED registry involves long-term commitment to realize its full benefits. As a consequence, the success of the IPTN is largely dependent on the willingness, dedication, and perseverance of participating centers to contribute data to the registry, to initiate and lead new IPTN study projects, and to participate in investigator-initiated academic trials and/or industry-sponsored regulatory trials. To succeed in obtaining highquality research data to improve care of children with thrombosis, the IPTN needs many dedicated clinicians all over the world, and multiple funding sources.

The IPTN has been initiated to enable international research collaboration, which is crucial to increase our knowledge about natural history, treatment, and outcomes of various types of pediatric TE.

Filling the knowledge gaps will improve the care for all neonates and children with thrombosis. The IPTN can only succeed through the dedication and hard work of all participating members to contribute data to the Throm-PED registry, and to develop, lead, or contribute to new IPTN projects. Only together can we advance the field of pediatric thrombosis.

We have no conflicts of interest to disclose. 

Incidence and mortality of venous thrombosis: a population-based study

Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study

Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE

Dramatic increase in venous thromboembolism in children's hospitals in the United States from

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors

Costs of venous thromboembolism, catheter-associated urinary tract infection, and pressure ulcer

Arterial Thrombosis

Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry

Epidemiology of venous thromboembolism in neonates and children

Venous thromboembolism occurring during adolescence

Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands

Neonatal central venous catheter thrombosis: diagnosis, management and outcome

Catheter-related arterial thrombosis in neonates and children: a systematic review

Perinatal arterial ischemic stroke

Evaluation and acute management of ischemic stroke in infants and children

Neonatal renal vein thrombosis: review of the English-language literature between 1992 and

How do we shift the paradigm of thinking in pediatric thrombosis and anticoagulation?

Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism

Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism

A phase II dose-finding study of dalteparin in children with VTE with or without cancer

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design

A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the safety of ApiXaban on pediatric heart disease on the preventioN of Embolism (SAXOPHONE) study

The Edoxaban Hokusai VTE PEDIATRICS study: an open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease

Disease registries and outcomes research in children: focus on lysosomal storage disorders

Patient registries for home oxygen research and evaluation

Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE)

Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis

fda-facts -postm arket -patie nt-regis try-ensur es-acces s-safe-and-effec tive-devices

From nonclinical research to clinical trials and patient-registries: challenges and opportunities in biomedical research

The importance of effective registries in pulmonary diseases and how to optimize their output

Recommendations for future research in catheter-related arterial thrombosis in children

Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: a systematic review

International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis